Accelerated detection of extended-spectrum β-lactamases in clinical isolates of enterobacteriaceae

British Journal of Biomedical Science

Volumn 63, Issue 4, 2006, Pages 151-154

  Kader, A A ^a   Kamath, K A ^a   Dass, S M ^a  

^a Almana General Hospital   (Saudi Arabia)

Author keywords

AmpC beta lactamases; beta Lactamases; Gram negative bacteria

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CARBAPENEM DERIVATIVE; CEFALEXIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG RESEARCH; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROVIDENCIA STUARTII;

ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA; PROTEUS MIRABILIS; PROVIDENCIA STUARTII;

EID: 33845953597     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2006.11732739     Document Type: Article

References (21)

1. Bush K. New β-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001; 32: 1085-9.
2. Rice LB, Bonomo RA. β-lactamases: which ones are clinically important? Drug Resistance Update 2000; 3: 178-89.
3. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.
4. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
5. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115: 529-35.
6. Paterson DL, Ko W, von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.
7. Performance standards for antimicrobial susceptibility testing. 14th informational supplement. Approved standard M100-S14. National Committee for Clinical Laboratory Standards, Wayne, Pa. 2004.
8. Jarlier V, Nicolas MH, Fournier G, Philippon A. ESBLs conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-78.
9. Kader AA, Angamuthu KK, Kamath KA, Zaman MN. Modified double-disc test for detection of extended-spectrum β-lactamases in Escherichia coli and Klebsiella pneumoniae. Br J Biomed Sci 2006; 63: 51-4.
10. Cowan SF, Steel KJ. Manual for identification of medical bacteria (3rd edn). Cambridge: Cambridge University Press, 1993: 140-3.
11. Tzelepi E, Giakkoupi P, Sofianou D, Loukova V, Kemeroglou A, Tsakris A. Detection of extended-spectrum β-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol 2000; 38: 542-6.
12. Weinbren MJ, Borthwick MA. Rapid detection of extended-spectrum β-lactamase (ESBL)-producing organisms in blood culture. J Antimicrob Chemother 2005; 55: 131-2.
13. Navon-Venezia S, Leavitt A, Ben-Ami R et al. Evaluation of an accelerated protocol for detection of extended-spectrum β-lactamase- producing Gram-negative bacilli from positive blood cultures. J Clin Microbiol 2005; 43: 439-41.
14. Navon-Venezia S, Ben-Ami R, Schwaber MJ, Leavitt A, Schwartz D, Carmeli Y. Protocol for the accelerated detection of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae from blood cultures. Eur J Clin Microbiol Infect Dis 2004; 2: 200-2.
15. Morlote MM, Navon-Venezia S, Carmeli Y, Venkataraman L, Gold HS. Presence of CTX-M-2 in Proteus mirabilis isolated in an Israeli hospital (Abstract). 43rd Interscience Conference. Antimicrob Agents Chemother 2003; C2-55.
16. Schlesinger J, Navon-Venezia S, Chlemintzki I, Hammer-Munz O, Schwaber M, Carmeli Y. Abstract. European Congress of Clinical Microbiology and Infectious Disease 2004.
17. Tumbarello M, Citton R, Spanu T et al. ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital. J Antimicrob Chemother 2004; 53: 277-82.
18. Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G. Occurrence of extended-spectrum β-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β-lactams and other antimicrobial drugs. Antimicrob Agents Chemother 2002; 46: 196-202.
19. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-33.
20. Livermore DM, Brown DJ, Quinn JP, Carmeli Y, Paterson DL, Yu VL. Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae? Clin Microbiol Infect Dis 2004; 10: 84-5.
21. Qin X, Weissman SJ, Chesnut MF, Zhang B, Shen L. Kirby-Bauer disc approximation to detect inducible third-generation cephalosporin resistance in Enterobacteriaceae. Ann Clin Microbiol Antimicrob 2004; 3: 13.